Profusa, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Profusa, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $100.0K | Apr 15, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.82M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($9.23M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.16M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.17M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $300.4K | Mar 6, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.71M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.50M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($1.51M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.27M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($45.0K) | Mar 6, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.61M | Apr 15, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.25M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.07M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($2.06M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($581.2K) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($662.4K) | Mar 6, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.0K | Apr 15, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.78M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.07M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $10.88M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $194.74M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $193.06M | Mar 6, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.43M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $57.13M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.09M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.83M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $7.32M | Mar 6, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.66M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($119.21M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($110.00M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($619.5K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($5.91M) | Feb 26, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($160.78M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($124.96M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($3.46M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($620.0K) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($5.91M) | Mar 6, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.78M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $191.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $4.5K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $193.5K | Feb 26, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (107) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (357) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 6, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (107) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (357) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 6, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.23M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 25,844 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 5.19M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 5.19M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 5.19M | Mar 6, 2023 |